BD (Becton, Dickinson and Company), a world leader in medical technology, has trusted CerTest Biotec as the manufacturer of the diagnostic kit for the new coronavirus, recently recognized with the CE mark (Directive 98/79 / EC). Available for laboratories, healthcare and diagnostic centers, the kit named VIASURE SARS-CoV-2 Real Time PCR Detection Kit is available for the professional use with the BD MAXTM automated system.
As Nelson Fernandes, General Manager at CerTest, said: “the kit we have developed offers a rapid diagnosis that allows the identification of COVID-19, so that the appropriate medical protocols can be established. It helps to reduce the actuation time to start the treatment with affected patients.“
The test developed for BD is based on the polymerase chain reaction in real time, identifying and amplifying a specific sequence of the virus DNA in clinical samples. The kit contains all the necessary components for the real-time PCR assay in a stabilized format, and includes an internal control to monitor the reaction. As this is a development for the BD MAXTM system, the test comes in the appropriate format for a proper use.
In the words of Nikos Pavlidis Vice President of Molecular Diagnosis, Women’s Health and Cancer for BD, “Together with CerTest, we can offer our customers in Europe a complete solution for COVID-19 diagnostics. Leveraging the significant install-base of the BD MAX System in Europe and other countries, we hope this kit will greatly enhance capacity for COVID-19 testing, thereby helping clinicians rapidly diagnose patients and ultimately prevent the spread of COVID-19.”
The BD MAX™ System is a fully-integrated, automated platform that performs nucleic acid extraction and real-time PCR providing results for up to 24 samples across multiple syndromes in less than three hours.
VIASURE SARS-CoV-2 Real Time PCR Detection Kit for the BD MAX™ System is sold through BD’s network and it is not available for sale in the United States.
Source, BD Press Release: